Do antibodies to beta2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome?
The aim of this study was to determine if the measurement of anti-beta2-glycoprotein I antibodies (abeta2-GPI) in serum levels contributes to the better characterization of the clinical situation of patients with antiphospholipid syndrome (APS). For this purpose abeta2-GPI of both isotypes was measu...
Gespeichert in:
| Veröffentlicht in: | Lupus 1999, Vol.8 (6), p.430-438 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 438 |
|---|---|
| container_issue | 6 |
| container_start_page | 430 |
| container_title | Lupus |
| container_volume | 8 |
| creator | Detkov Gil-Aguado, A Lavilla, P Cuesta, M V Fontán, G Pascual-Salcedo, D |
| description | The aim of this study was to determine if the measurement of anti-beta2-glycoprotein I antibodies (abeta2-GPI) in serum levels contributes to the better characterization of the clinical situation of patients with antiphospholipid syndrome (APS). For this purpose abeta2-GPI of both isotypes was measured in 42 patients with APS and 32 SLE patients without APS. Clinical records of all patients were thoroughly reviewed. The presence of abeta2-GPI was correlated with the clinical manifestations of APS and compared with the presence of anticardiolipin antibodies (aCL) and lupus anticoagulant (LA) activity. There was a positive correlation between levels of aCL and abeta2-GPI for both IgG and IgM isotypes (rho of Spearman=0.82 and 0. 64 respectively, P=0.0001). Both antibodies presented significantly higher titres in LA positive patients (P |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70035054</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70035054</sourcerecordid><originalsourceid>FETCH-LOGICAL-p540-e67256f6405e6abee4218932d3601be119717d3b6adc40b8babba24514ee98ad3</originalsourceid><addsrcrecordid>eNo1kM1OwzAQhH0A0VJ4BeQTt0jr2HGSE0LlV6rEpfdoHW-pURKntnMoT08K5TDakebTSDsXbAm1FlkOUi7YdYxfACBFra_YQoCqJAhYssOT5zgkZ7x1FHny3FDCPPvsjq0fg0_kBi5464cUnJkSnZC0pxOWKPB2jwHb2blvTM4P3O9-41PnuPdxVudGZ3k8Djb4nh5u2OUOu0i357ti25fn7fot23y8vq8fN9lYKMhIl3mhd1pBQRoNkcpFVcvcSg3CkBB1KUorjUbbKjCVQWMwV4VQRHWFVq7Y_V_t_MRhopia3sWWug4H8lNsynmMAgo1g3dncDI92WYMrsdwbP43kj-6t2Pe</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70035054</pqid></control><display><type>article</type><title>Do antibodies to beta2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome?</title><source>SAGE Complete A-Z List</source><source>MEDLINE</source><creator>Detkov ; Gil-Aguado, A ; Lavilla, P ; Cuesta, M V ; Fontán, G ; Pascual-Salcedo, D</creator><creatorcontrib>Detkov ; Gil-Aguado, A ; Lavilla, P ; Cuesta, M V ; Fontán, G ; Pascual-Salcedo, D</creatorcontrib><description>The aim of this study was to determine if the measurement of anti-beta2-glycoprotein I antibodies (abeta2-GPI) in serum levels contributes to the better characterization of the clinical situation of patients with antiphospholipid syndrome (APS). For this purpose abeta2-GPI of both isotypes was measured in 42 patients with APS and 32 SLE patients without APS. Clinical records of all patients were thoroughly reviewed. The presence of abeta2-GPI was correlated with the clinical manifestations of APS and compared with the presence of anticardiolipin antibodies (aCL) and lupus anticoagulant (LA) activity. There was a positive correlation between levels of aCL and abeta2-GPI for both IgG and IgM isotypes (rho of Spearman=0.82 and 0. 64 respectively, P=0.0001). Both antibodies presented significantly higher titres in LA positive patients (P<0.05). The specificity for APS was 91% for IgG abeta2-GPI vs 75% for IgG aCL and 87% for IgM abeta2-GPI vs 81% for IgM aCL. 68% of patients with thrombosis of 100% of patients with thrombocytopenia showed positive tests for all three markers (aCL, LA, abeta2-GPI). Simultaneous presence of circulating LA and high titres of both aCL and abeta2-GPI identify a subset of patients with primary APS (PAPS) who have a more severe clinical course of the disease. Although the specificity of abeta2-GPI IgG is higher than that of aCL IgG, when all three tests are performed abeta2-GPI testing provides only additional information to that of aCL and LA. Therefore, we concluded that the abeta2-GPI test should not be considered as a substitute for conventional LA or aCL assays. However, performance of abeta2-GPI seems to be important in PAPS with high aCL titres, to alert the physician about the risk for the worst course of the illness.</description><identifier>ISSN: 0961-2033</identifier><identifier>PMID: 10483010</identifier><language>eng</language><publisher>England</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibody Specificity ; Antiphospholipid Syndrome - immunology ; Autoantibodies - immunology ; beta 2-Glycoprotein I ; Female ; Glycoproteins - immunology ; Humans ; Immunoglobulin Isotypes - immunology ; Lupus Coagulation Inhibitor - immunology ; Male ; Middle Aged</subject><ispartof>Lupus, 1999, Vol.8 (6), p.430-438</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4009</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10483010$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Detkov</creatorcontrib><creatorcontrib>Gil-Aguado, A</creatorcontrib><creatorcontrib>Lavilla, P</creatorcontrib><creatorcontrib>Cuesta, M V</creatorcontrib><creatorcontrib>Fontán, G</creatorcontrib><creatorcontrib>Pascual-Salcedo, D</creatorcontrib><title>Do antibodies to beta2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome?</title><title>Lupus</title><addtitle>Lupus</addtitle><description>The aim of this study was to determine if the measurement of anti-beta2-glycoprotein I antibodies (abeta2-GPI) in serum levels contributes to the better characterization of the clinical situation of patients with antiphospholipid syndrome (APS). For this purpose abeta2-GPI of both isotypes was measured in 42 patients with APS and 32 SLE patients without APS. Clinical records of all patients were thoroughly reviewed. The presence of abeta2-GPI was correlated with the clinical manifestations of APS and compared with the presence of anticardiolipin antibodies (aCL) and lupus anticoagulant (LA) activity. There was a positive correlation between levels of aCL and abeta2-GPI for both IgG and IgM isotypes (rho of Spearman=0.82 and 0. 64 respectively, P=0.0001). Both antibodies presented significantly higher titres in LA positive patients (P<0.05). The specificity for APS was 91% for IgG abeta2-GPI vs 75% for IgG aCL and 87% for IgM abeta2-GPI vs 81% for IgM aCL. 68% of patients with thrombosis of 100% of patients with thrombocytopenia showed positive tests for all three markers (aCL, LA, abeta2-GPI). Simultaneous presence of circulating LA and high titres of both aCL and abeta2-GPI identify a subset of patients with primary APS (PAPS) who have a more severe clinical course of the disease. Although the specificity of abeta2-GPI IgG is higher than that of aCL IgG, when all three tests are performed abeta2-GPI testing provides only additional information to that of aCL and LA. Therefore, we concluded that the abeta2-GPI test should not be considered as a substitute for conventional LA or aCL assays. However, performance of abeta2-GPI seems to be important in PAPS with high aCL titres, to alert the physician about the risk for the worst course of the illness.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibody Specificity</subject><subject>Antiphospholipid Syndrome - immunology</subject><subject>Autoantibodies - immunology</subject><subject>beta 2-Glycoprotein I</subject><subject>Female</subject><subject>Glycoproteins - immunology</subject><subject>Humans</subject><subject>Immunoglobulin Isotypes - immunology</subject><subject>Lupus Coagulation Inhibitor - immunology</subject><subject>Male</subject><subject>Middle Aged</subject><issn>0961-2033</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kM1OwzAQhH0A0VJ4BeQTt0jr2HGSE0LlV6rEpfdoHW-pURKntnMoT08K5TDakebTSDsXbAm1FlkOUi7YdYxfACBFra_YQoCqJAhYssOT5zgkZ7x1FHny3FDCPPvsjq0fg0_kBi5464cUnJkSnZC0pxOWKPB2jwHb2blvTM4P3O9-41PnuPdxVudGZ3k8Djb4nh5u2OUOu0i357ti25fn7fot23y8vq8fN9lYKMhIl3mhd1pBQRoNkcpFVcvcSg3CkBB1KUorjUbbKjCVQWMwV4VQRHWFVq7Y_V_t_MRhopia3sWWug4H8lNsynmMAgo1g3dncDI92WYMrsdwbP43kj-6t2Pe</recordid><startdate>1999</startdate><enddate>1999</enddate><creator>Detkov</creator><creator>Gil-Aguado, A</creator><creator>Lavilla, P</creator><creator>Cuesta, M V</creator><creator>Fontán, G</creator><creator>Pascual-Salcedo, D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>1999</creationdate><title>Do antibodies to beta2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome?</title><author>Detkov ; Gil-Aguado, A ; Lavilla, P ; Cuesta, M V ; Fontán, G ; Pascual-Salcedo, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p540-e67256f6405e6abee4218932d3601be119717d3b6adc40b8babba24514ee98ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibody Specificity</topic><topic>Antiphospholipid Syndrome - immunology</topic><topic>Autoantibodies - immunology</topic><topic>beta 2-Glycoprotein I</topic><topic>Female</topic><topic>Glycoproteins - immunology</topic><topic>Humans</topic><topic>Immunoglobulin Isotypes - immunology</topic><topic>Lupus Coagulation Inhibitor - immunology</topic><topic>Male</topic><topic>Middle Aged</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Detkov</creatorcontrib><creatorcontrib>Gil-Aguado, A</creatorcontrib><creatorcontrib>Lavilla, P</creatorcontrib><creatorcontrib>Cuesta, M V</creatorcontrib><creatorcontrib>Fontán, G</creatorcontrib><creatorcontrib>Pascual-Salcedo, D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Detkov</au><au>Gil-Aguado, A</au><au>Lavilla, P</au><au>Cuesta, M V</au><au>Fontán, G</au><au>Pascual-Salcedo, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Do antibodies to beta2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome?</atitle><jtitle>Lupus</jtitle><addtitle>Lupus</addtitle><date>1999</date><risdate>1999</risdate><volume>8</volume><issue>6</issue><spage>430</spage><epage>438</epage><pages>430-438</pages><issn>0961-2033</issn><abstract>The aim of this study was to determine if the measurement of anti-beta2-glycoprotein I antibodies (abeta2-GPI) in serum levels contributes to the better characterization of the clinical situation of patients with antiphospholipid syndrome (APS). For this purpose abeta2-GPI of both isotypes was measured in 42 patients with APS and 32 SLE patients without APS. Clinical records of all patients were thoroughly reviewed. The presence of abeta2-GPI was correlated with the clinical manifestations of APS and compared with the presence of anticardiolipin antibodies (aCL) and lupus anticoagulant (LA) activity. There was a positive correlation between levels of aCL and abeta2-GPI for both IgG and IgM isotypes (rho of Spearman=0.82 and 0. 64 respectively, P=0.0001). Both antibodies presented significantly higher titres in LA positive patients (P<0.05). The specificity for APS was 91% for IgG abeta2-GPI vs 75% for IgG aCL and 87% for IgM abeta2-GPI vs 81% for IgM aCL. 68% of patients with thrombosis of 100% of patients with thrombocytopenia showed positive tests for all three markers (aCL, LA, abeta2-GPI). Simultaneous presence of circulating LA and high titres of both aCL and abeta2-GPI identify a subset of patients with primary APS (PAPS) who have a more severe clinical course of the disease. Although the specificity of abeta2-GPI IgG is higher than that of aCL IgG, when all three tests are performed abeta2-GPI testing provides only additional information to that of aCL and LA. Therefore, we concluded that the abeta2-GPI test should not be considered as a substitute for conventional LA or aCL assays. However, performance of abeta2-GPI seems to be important in PAPS with high aCL titres, to alert the physician about the risk for the worst course of the illness.</abstract><cop>England</cop><pmid>10483010</pmid><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0961-2033 |
| ispartof | Lupus, 1999, Vol.8 (6), p.430-438 |
| issn | 0961-2033 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70035054 |
| source | SAGE Complete A-Z List; MEDLINE |
| subjects | Adolescent Adult Aged Aged, 80 and over Antibody Specificity Antiphospholipid Syndrome - immunology Autoantibodies - immunology beta 2-Glycoprotein I Female Glycoproteins - immunology Humans Immunoglobulin Isotypes - immunology Lupus Coagulation Inhibitor - immunology Male Middle Aged |
| title | Do antibodies to beta2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T04%3A03%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Do%20antibodies%20to%20beta2-glycoprotein%201%20contribute%20to%20the%20better%20characterization%20of%20the%20antiphospholipid%20syndrome?&rft.jtitle=Lupus&rft.au=Detkov&rft.date=1999&rft.volume=8&rft.issue=6&rft.spage=430&rft.epage=438&rft.pages=430-438&rft.issn=0961-2033&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E70035054%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70035054&rft_id=info:pmid/10483010&rfr_iscdi=true |